drugset

drugset / Trial / NCT00729313

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

NCT00729313 ↗

Phase 3 Completed 111 enrolled Ipsen

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the protocol, is to determine whether lanreotide 30 mg is effective in the treatment of patients with digestive fistulae.

Timeline

Start: 2000-04
Primary completion: 2005-04
Completion: 2005-04

Publications

Results Gayral F, Campion JP, Regimbeau JM, Blumberg J, Maisonobe P, Topart P, Wind P; Lanreotide Digestive Fistula. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Ann Surg. 2009 Dec;250(6):872-7. doi: 10.1097/sla.0b013e3181b2489f.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lanreotide	Other / unclassified	30 mg	Intramuscular

Indications